Commercial Potential of the Forthcoming US Biosimilars Market

An Addendum to "Specialty Physicians Discuss their Opinions of the United States Biosimilars Market"

USD 3,950.00

* Required Fields

USD 3,950.00


Be the first to review this product

Frost & Sullivan assessed physicians’ willingness to prescribe biosimilars in the United States. The objective of this research was to conduct a highly qualitative analysis of a representative sample of 20 preselected practicing specialty physicians in the United States in the spirit of an interactive roundtable discussion. The primary goal was to encourage participants to freely express opinions and ideas around all aspects of a topic, facilitating a free exchange about how biosimilars will impact their practice and the overall US healthcare market. The biosimilar research panel was conducted over a three-day period (October 11-13, 2011). Questions and discussions were designed to gauge both short-term and l

Table of Contents

Commercial Potential of the Forthcoming US Biosimilars MarketSpecialty Physicians Panel Discussion of BiosimilarsUS Specialty Physicians Discuss Biosimilars Market

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.